ODTX (Odyssey Therapeutics) 5-Year Yield-on-Cost %: 0.00 (As of Aug. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ODTX Odyssey Therapeutics Inc ODTX
13 GF Score
Price $26.49
! 2 Warning Signs
View Full Analysis

What is Odyssey Therapeutics 5-Year Yield-on-Cost %?

Odyssey Therapeutics ODTX +6.93% 13 5-Year Yield-on-Cost % is 0.00 as of Aug. 24, 2026. GuruFocus rates ODTX with a GF Score™ of 13/100. The stock has 2 warning signs investors should review. Among 150 Biotechnology companies, Odyssey Therapeutics ranks worse than 666666% on this metric.

Odyssey Therapeutics's yield on cost for the quarter that ended in Jun. 2026 was 0.00.


The historical rank and industry rank for Odyssey Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:



ODTX's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.65
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Odyssey Therapeutics  (NAS:ODTX) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Odyssey Therapeutics 5-Year Yield-on-Cost % Related Terms


ODTX vs SANA, GERN, PHAT: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, Odyssey Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Odyssey Therapeutics 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Odyssey Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Odyssey Therapeutics's 5-Year Yield-on-Cost % falls into.


ODTX
13GF Score
Odyssey Therapeutics Inc ODTX
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Odyssey Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Odyssey Therapeutics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Odyssey Therapeutics (ODTX) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 24, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Odyssey Therapeutics and its competitors. According to the industry distribution chart, Odyssey Therapeutics ranks #999999 out of 150 companies in the Biotechnology industry.
Is Odyssey Therapeutics' 5-Year Yield-on-Cost % too high?
Odyssey Therapeutics' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Odyssey Therapeutics ranks #999999 out of 150 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Odyssey Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Odyssey Therapeutics' 5-Year Yield-on-Cost % compare to SANA and GERN?
According to the Biotechnology industry distribution chart, Odyssey Therapeutics ranks #999999 out of 150 companies for 5-Year Yield-on-Cost %. This places Odyssey Therapeutics in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.65, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Odyssey Therapeutics and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Odyssey Therapeutics's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Odyssey Therapeutics stock overvalued right now?
Odyssey Therapeutics (ODTX) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Odyssey Therapeutics' overall GF Score™ is 13/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Odyssey Therapeutics (ODTX), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Odyssey Therapeutics Business Description

Address 51 Sleeper Street, Boston, MA, USA, 02210
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
13GF Score

Get the complete analysis for ODTX

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.49
Price